Osteoblast–osteoclast interactions

References

• Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 2008;473:201–209.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Park KA, Ito M, Ikeda K, Takeshita S. Osteoclast-derived complement component 3a stimulates osteoblast differentiation. J Bone Miner Res 2014;29:1522–1530.
   PubMed Web of Science ®Google Scholar
• Zaidi M. Skeletal remodeling in health and disease. Nat Med 2007;13:791–801.
   PubMed Web of Science ®Google Scholar
• Tamma R, Zallone A. Osteoblast and osteoclast crosstalks: from OAF to Ephrin. Inflamm Allergy Drug Targets 2012;11:196–200.
   PubMedGoogle Scholar
• Mundy GR, Elefteriou F. Boning up on ephrin signaling. Cell 2006;126:441–443.
   PubMed Web of Science ®Google Scholar
• Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption–a hypothesis. Calcif Tissue Int 1981;33:349–351.
   PubMed Web of Science ®Google Scholar
• Wang L, Liu S, Zhao Y, Liu D, Liu Y, Chen C, Karray S, Shi S, Jin Y. Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass. Cell Death Differ 2015;22:1654–1664.
   PubMed Web of Science ®Google Scholar
• Everts V, Delaisse JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, Beertsen W. The bone lining cell: its role in cleaning Howship’s lacunae and initiating bone formation. J Bone Miner Res 2002;17:77–90.
   PubMed Web of Science ®Google Scholar
• Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006;4:111–121.
   PubMed Web of Science ®Google Scholar
• Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP, Weitzmann MN. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007;109:3839–3848.
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–319.
   PubMed Web of Science ®Google Scholar
• Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260–1268.
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337–342.
   PubMed Web of Science ®Google Scholar
• Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15:457–475.
   PubMed Web of Science ®Google Scholar
• Chamoux E, Houde N, L’Eriger K, Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol 2008;216:536–542.
   PubMed Web of Science ®Google Scholar
• Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel RH, Takayanagi H. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011;17:1473–1480.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H. Osteoprotection by semaphorin 3A. Nature 2012;485:69–74.
   PubMed Web of Science ®Google Scholar
• Lacey DL, Erdmann JM, Shima M, Kling S, Matayoshi A, Ohara J, Perkins SL. Interleukin 4 enhances osteoblast macrophage colony-stimulating factor, but not interleukin 6, production. Calcif Tissue Int 1994;55:21–28.
   PubMed Web of Science ®Google Scholar
• Wiktor-Jedrzejczak W, Bartocci A, Ferrante AJ, Ahmed-Ansari A, Sell KW, Pollard JW, Stanley ER. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 1990;87:4828–4832.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim N. Signaling pathways in osteoclast differentiation. Chonnam Med J 2016;52:12–17.
   PubMedGoogle Scholar
• Sambandam Y, Blanchard JJ, Daughtridge G, Kolb RJ, Shanmugarajan S, Pandruvada SN, Bateman TA, Reddy SV. Microarray profile of gene expression during osteoclast differentiation in modelled microgravity. J Cell Biochem 2010;111:1179–1187.
   PubMed Web of Science ®Google Scholar
• Woo KM, Kim HM, Ko JS. Macrophage colony-stimulating factor promotes the survival of osteoclast precursors by up-regulating Bcl-X(L). Exp Mol Med 2002;34:340–346.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Miyazaki T, Fukuda A, Akiyama T, Kadono Y, Wakeyama H, Kono S, Hoshikawa S, Nakamura M, Ohshima Y, Hikita A, Nakamura I, Nakamura K. Molecular mechanism of the life and death of the osteoclast. Ann N Y Acad Sci 2006;1068:180–186.
   PubMed Web of Science ®Google Scholar
• Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res 2013;28:711–722.
   PubMed Web of Science ®Google Scholar
• Graves DT, Jiang Y, Valente AJ. The expression of monocyte chemoattractant protein-1 and other chemokines by osteoblasts. Front Biosci 1999;4:D571–D580.
   PubMedGoogle Scholar
• Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem 2007;282:33098–33106.
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–176.
   PubMed Web of Science ®Google Scholar
• The American Society for Bone and Mineral Research President’s Committee on Nomenclature. Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J Bone Miner Res 2000;15:2293–2296.
   Google Scholar
• Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008;29:155–192.
   PubMed Web of Science ®Google Scholar
• Ikeda T, Kasai M, Utsuyama M, Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 2001;142:1419–1426.
   PubMed Web of Science ®Google Scholar
• Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000;103:41–50.
   PubMed Web of Science ®Google Scholar
• Kim NS, Kim HJ, Koo BK, Kwon MC, Kim YW, Cho Y, Yokota Y, Penninger JM, Kong YY. Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol 2006;26:1002–1013.
   PubMed Web of Science ®Google Scholar
• Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci. 2007 Nov;1116:227–237.
   PubMed Web of Science ®Google Scholar
• Kim HH, Lee DE, Shin JN, Lee YS, Jeon YM, Chung CH, Ni J, Kwon BS, Lee ZH. Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 1999;443:297–302.
   PubMed Web of Science ®Google Scholar
• Luo J, Yang Z, Ma Y, Yue Z, Lin H, Qu G, Huang J, Dai W, Li C, Zheng C, Xu L, Chen H, Wang J, Li D, Siwko S, Penninger JM, Ning G, Xiao J, Liu M. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nature Med 2016;22:539–546.
   PubMed Web of Science ®Google Scholar
• Hosogaya S, Yatomi Y, Nakamura K, Ohkawa R, Okubo S, Yokota H, Ohta M, Yamazaki H, Koike T, Ozaki Y. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann Clin Biochem 2008;45:364–368.
   PubMed Web of Science ®Google Scholar
• Sims SM, Panupinthu N, Lapierre DM, Pereverzev A, Dixon SJ. Lysophosphatidic acid: a potential mediator of osteoblast–osteoclast signaling in bone. Biochimica Biophysica Acta 2013;1831:109–116.
   PubMed Web of Science ®Google Scholar
• Panupinthu N, Rogers JT, Zhao L, Solano-Flores LP, Possmayer F, Sims SM, Dixon SJ. P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. J Cell Biol 2008;181:859–871.
   PubMed Web of Science ®Google Scholar
• Del Fattore A, Teti A, Rucci N. Osteoclast receptors and signaling. Arch Biochem Biophys 2008;473:147–160.
   PubMed Web of Science ®Google Scholar
• McMichael BK, Meyer SM, Lee BS. c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation. J Biol Chem 2010;285:26641–26651.
   PubMed Web of Science ®Google Scholar
• David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, Serre CM, Grès S, Bendriss-Vermare N, Bollen M, Saez S, Aoki J, Saulnier-Blache JS, Clézardin P, Peyruchaud O. Cancer cell expression of autotaxin controls bone metastasis in mouse through lysophosphatidic acid-dependent activation of osteoclasts PLoS One 2010;5:e9741.
   Google Scholar
• Lapierre DM, Tanabe N, Pereverzev A, Spencer M, Shugg RP, Dixon SJ, Sims SM. Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate cytosolic calcium concentration, evoke retraction, and promote cell survival. J Biol Chem 2010;285:25792–25801.
   PubMed Web of Science ®Google Scholar
• Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O’Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002;298:843–846.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007;130:811–823.
   PubMed Web of Science ®Google Scholar
• Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008;27:535–545.
   PubMed Web of Science ®Google Scholar
• Garcia AJ, Tom C, Guemes M, Polanco G, Mayorga ME, Wend K, Miranda-Carboni GA, Krum SA. ER alpha signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis. J Bone Miner Res 2013;28:283–290.
   PubMed Web of Science ®Google Scholar
• Rho J, Altmann CR, Socci ND, Merkov L, Kim N, So H, Lee O, Takami M, Brivanlou AH, Choi Y. Gene expression profiling of osteoclast differentiation by combined suppression subtractive hybridization (SSH) and cDNA microarray analysis. DNA Cell Biol 2002;21:541–549.
   PubMed Web of Science ®Google Scholar
• Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK, Pignolo RJ, Koczon-Jaremko B, Lorenzo J, Choi Y. V-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 2006;12:1403–1409.
   PubMed Web of Science ®Google Scholar
• Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel RH, Takayanagi H. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011;17:1473–1480.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei L, Miron RJ, Shi B, Bian Z. Anabolic bone formation via a site-specific bone-targeting delivery system by interfering with semaphorin 4D expression. J Bone Miner Res 2015;30:286–296.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei L, Miron RJ, Shi B, Bian Z. Bone scaffolds loaded with siRNA-Semaphorin4d for the treatment of osteoporosis related bone defects. Sci Rep 2016;6:26925.
   PubMed Web of Science ®Google Scholar
• Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10:537–543.
   PubMed Web of Science ®Google Scholar
• Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003;22:6267–6276.
   PubMed Web of Science ®Google Scholar
• Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003;278:24113–24117.
   PubMed Web of Science ®Google Scholar
• Ota K, Quint P, Ruan M, Pederson L, Westendorf JJ, Khosla S, Oursler MJ. Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. J Cell Biochem 2013;114:1901–1907.
   PubMed Web of Science ®Google Scholar
• Lian JB, Stein GS, van Wijnen AJ, Stein JL, Hassan MQ, Gaur T, Zhang Y. MicroRNA control of bone formation and homeostasis. Nat Rev Endocrinol 2012;8:212–227.
   PubMed Web of Science ®Google Scholar
• Shi K, Lu J, Zhao Y, Wang L, Li J, Qi B, Li H, Ma C. MicroRNA-214 suppresses osteogenic differentiation of C2C12 myoblast cells by targeting Osterix. Bone 2013;55:487–494.
   PubMed Web of Science ®Google Scholar
• Wang X, Guo B, Li Q, Peng J, Yang Z, Wang A, Li D, Hou Z, Lv K, Kan G, et al. MiR-214 targets ATF4 to inhibit bone formation. Nat Med. 2013;19:93–100.
   PubMed Web of Science ®Google Scholar
• Li D, Liu J, Guo B, Liang C, Dang L, Lu C, He X, Cheung HY, Xu L, Lu C, He X, Cheung HY, Xu L, Lu C, He B, Liu B, Shaikh AB, Li F, Wang L, Yang Z, Au DW, Peng S, Zhang Z, Zhang BT, Pan X, Qian A, Shang P, Xiao L, Jiang B, Wong CK, Xu J, Bian Z, Liang Z, Guo DA, Zhu H, Tan W, Lu A, Zhang G. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Commun 2016;7:10872.
   PubMed Web of Science ®Google Scholar
• Sun W, Zhao C, Li Y, Wang L, Nie G, Peng J, Wang A, Zhang P, Tian W, Li Q, Song J, Wang C, Xu X, Tian Y, Zhao D, Xu Z, Zhong G, Han B, Ling S, Chang YZ, Li Y. Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discovery 2016;31(2):16015.
   Web of Science ®Google Scholar
• Takeshita S, Fumoto T, Matsuoka K, Park KA, Aburatani H, Kato S, Ito M, Ikeda K. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J Clin Invest 2013;123:3914–3924.
   PubMed Web of Science ®Google Scholar
• Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, Kim HH. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J 2006;25:5840–5851.
   PubMed Web of Science ®Google Scholar
• Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A. 2008;105:20764–20769.
   PubMed Web of Science ®Google Scholar
• Grano M, Galimi F, Zambonin G, Colucci S, Cottone E, Zallone AZ, Comoglio PM. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA 1996;93:7644–7648.
   PubMed Web of Science ®Google Scholar
• Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res. 2001;16:1444–1452.
   PubMed Web of Science ®Google Scholar
• Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Luth A, Koskivirta I, Kleuser B, Vacher J, Vuorio E, Horne WC, Baron R. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest 2013;123:666–681.
   PubMed Web of Science ®Google Scholar
• Teti A. Mechanisms of osteoclast-dependent bone formation. Bonekey Rep 2013;2:449.
   PubMedGoogle Scholar
• Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, Zhao L, Nagy TR, Peng X, Hu J, Feng X, Van Hul W, Wan M, Cao X. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009;15:757–765.
   PubMed Web of Science ®Google Scholar
• Weivoda MM, Ruan M, Pederson L, Hachfeld C, Davey RA, Zajac JD, Westendorf JJ, Khosla S, Oursler MJ. Osteoclast tgf-β receptor signaling induces wnt1 secretion and couples bone resorption to bone formation. J Bone Miner Res 2016;3:76–85
   Web of Science ®Google Scholar
• Xian L, Wu X, Pang L, Lou M, Rosen CJ, Qiu T, Crane J, Frassica F, Zhang L, Rodriguez JP, Jia X, Yakar S, Xuan S, Efstratiadis A, Wan M, Cao X. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 2012;18:1095–1101.
   PubMed Web of Science ®Google Scholar